Premium
miRNA‐Specific Unlocking of Drug‐Loaded Metal–Organic Framework Nanoparticles: Targeted Cytotoxicity toward Cancer Cells
Author(s) -
Chen WeiHai,
Luo GuoFeng,
Sohn Yang Sung,
Nechushtai Rachel,
Willner Itamar
Publication year - 2019
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201900935
Subject(s) - cytotoxicity , microrna , cancer cell , exonuclease iii , ovarian cancer , chemistry , doxorubicin , drug delivery , biophysics , microbiology and biotechnology , cancer research , nanotechnology , biochemistry , biology , cancer , materials science , gene , in vitro , genetics , chemotherapy , escherichia coli
UiO‐68 metal–organic framework nanoparticles (NMOFs) are loaded with a doxorubicin drug (fluorescent dye analogs) and locked by means of structurally engineered duplex nucleic acid structures, where one strand is covalently linked to the NMOFs and the second strand is hybridized with the anchor strand. Besides the complementarity of the second strand to the anchor sequence, it includes the complementary sequence to the microRNAs (miRNA)‐21 or miRNA‐221 that is specific miRNA biomarker for MCF‐7 breast cancer cells or OVCAR‐3 ovarian cancer cells. In the presence of the respective miRNA biomarkers, the miRNA‐induced displacement of the strand associated with the anchor strand proceeds, resulting in the release of DNA/miRNA duplexes. The released duplexes are, however, engineered to be digested in the presence of exonuclease III, Exo III, a process that recycles the miRNAs and provides the autonomous amplified unlocking of the NMOFs and the release of the doxorubicin load (or the fluorescent dye analogs) even at low concentrations of miRNA. Preliminary cell experiments reveal that the respective NMOFs are unlocked by the miRNA‐21 or miRNA‐221, resulting in selective cytotoxicity toward MCF‐7 breast cancer cells or OVCAR‐3 ovarian cancer cells.